Loading provider…
Loading provider…
Hematology (Internal Medicine) Physician in Thomasville, NC
NPI: 1326304353Primary Practice Location
NOVANT HEALTH THOMASVILLE MEDICAL CENTER
207 Old Lexington Rd, Thomasville, NC
Primary Employer
NH Thomasville Cancer Clinics
novanthealth.org
HQ Phone
Get MD James's Phone Numberphone_androidMobile
Get MD James's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
NC State Medical License
NC State Medical License
2019 - 2026
OH State Medical License
2014 - 2021
CO State Medical License
2017 - 2019

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
UNR Med
med.unr.edu
Medical School
Until 2012
University of Colorado
Fellowship • Hematology and Medical Oncology
2016 - 2019
Ohio State University Hospital
Residency • Internal Medicine/Pediatrics
2012 - 2016
University of Oregon
2000 - 2005
2000 - 2005
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 67 | 308 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 57 | 101 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 39 | 183 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 26 | 33 |
| 5 | 99239Hospital discharge day management, more than 30 minutes | 23 | 27 |
COVID-19 in patients with acute leukemia: Two cases with different outcomes.
Authors: Jan Moreb
Publication Date: 2020-07-07
Authors: Hayley Knollman, Elena Shagisultanova, Peter Hulick
Journal: Cancer Med
Publication Date: 2019-08-12
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Bone Marrow Biopsy, DRUG: Venetoclax, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, DRUG: Busulfan, DRUG: Azacitidine, DRUG: Liposome-encapsulated Daunorubicin-Cytarabine, DRUG: Cytarabine, OTHER: Best Practice, DRUG: Melphalan, PROCEDURE: Computed Tomography, PROCEDURE: Multigated Acquisition Scan, DRUG: Enasidenib, DRUG: Fludarabine, PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation, DRUG: Placebo Administration, RADIATION: Total-Body Irradiation, PROCEDURE: Bone Marrow Aspiration, PROCEDURE: Biopsy Procedure, DRUG: Gemtuzumab Ozogamicin, PROCEDURE: Echocardiography Test, DRUG: Gilteritinib, DRUG: Daunorubicin Hydrochloride, PROCEDURE: Chest Radiography, DRUG: Decitabine and Cedazuridine, PROCEDURE: Mutation Carrier Screening, DRUG: Olutasidenib
Lead Sponsor: Ascentage Pharma Group Inc.
Intervention / Treatment: DRUG: APG 2575 ramp up arm
Lead Sponsor: Syros Pharmaceuticals
Intervention / Treatment: DRUG: Placebo, DRUG: Azacitidine, DRUG: Tamibarotene